New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ARRY From The Last 14 Days
Check below for free stories on ARRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
06:41 EDTARRYArray BioPharma shares attractive at current levels, says Piper Jaffray
Piper Jaffray says shares of Array BioPharma are attractive at current levels ahead of Phase III data readouts for binimetinib in melanoma, selumetinib in Kras-mutant lung, thyroid and uveal melanoma, and filanesib in multiple myeloma. Piper sees the biggest overhang on Array shares as being the financing requirement and it notes that binimetinib could be returned to the company from current partner Novartis (NVS). Nonetheless, it feels investors should take a "serious look" at Array and keeps an Overweight rating on the stock with a $9 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use